Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506262 | 0.83 | NAMPT (0.60) | NAMPTHTTPOLBHPGDMEN1 | |
| SCHEMBL19592503 | 0.82 | HTT (0.54) | NAMPTHTTPOLBHPGDNPSR1 | |
| SCHEMBL6976261 | 0.82 | LMNA (0.49) | HTTPOLBKMT2AHDAC3HDAC1 | |
| SCHEMBL21470612 | 0.81 | ANO1 (0.57) | NAMPTPOLBHPGDNPSR1MEN1 | |
| SCHEMBL5940572 | 0.81 | HTT (0.52) | NAMPTHTTPOLBHPGDNPSR1 | |
| SCHEMBL20193359 | 0.81 | HTT (0.52) | NAMPTHTTPOLBHPGDNPSR1 | |
| SCHEMBL25767472 | 0.81 | HTT (0.52) | NAMPTHTTPOLBHPGDNPSR1 | |
| SCHEMBL25780577 | 0.81 | KDM4E (0.61) | NAMPTHTTPOLBHPGDNPSR1 | |
| SCHEMBL25781021 | 0.81 | L3MBTL1 (0.61) | NAMPTHTTPOLBMEN1ALDH1A1 | |
| SCHEMBL4516395 | 0.80 | POLB (0.71) | NAMPTHTTPOLBHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934264-B1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER (US) | 2003-09-10 | — | — | EP | claimed |
| US-6313302-B2 | OPIOID KAPPA RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; ANALGESICS, ANTIINFLAMMATORY AGENTS, ANESTHETICS, AND NEUROPROTECTANTS | PFIZER INC. | 2001-11-06 | — | — | US | claimed |
| US-20010014683-A1 | Analgesics; side effect reduction | ITO FUMITAKA (JP) | 2001-08-16 | — | — | US | claimed |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | ITO FUMITAKA (JP) | 2001-07-19 | — | — | US | claimed |
| EP-0934264-B1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6313302-B2 | OPIOID KAPPA RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; ANALGESICS, ANTIINFLAMMATORY AGENTS, ANESTHETICS, AND NEUROPROTECTANTS | PFIZER INC. | 2001-11-06 | — | — | US | disclosed |
| US-6310061-B2 | OPIOID RECEPTOR SUBTYPE KAPPA; USE AS ANALGESIC, ANESTHETIC, ANTIINFLAMMATORY OR NEUROPROTECTIVE AGENT, FOR TREATMENT OF ARTHRITIS, STROKE OR FUNCTIONAL BOWEL DISEASE; REDUCED DRUG DEPENDENCY SIDE EFFECTS | PFIZER INC. | 2001-10-30 | — | — | US | disclosed |
| US-6307061-B2 | USEFUL AS AN ANALGESIC, ANESTHETIC, ANTI-INFLAMMATORY OR NEUROPROTECIVE AGENT | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6303602-B1 | USEFUL AS ANALGESIC, ANESTHETIC, ANTI-INFLAMMATORY OR NEUROPROTECTIVE AGENT, OR FOR THERAPY OF ARTHRITIS, STROKE OF FUNCTIONAL BOWEL DISEASE | PFIZER INC. | 2001-10-16 | — | — | US | disclosed |
| US-6294557-B1 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-6294569-B2 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-20010020024-A1 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists | ITO FUMITAKA (JP) | 2001-09-06 | — | — | US | disclosed |
| US-20010014683-A1 | Analgesics; side effect reduction | ITO FUMITAKA (JP) | 2001-08-16 | — | — | US | disclosed |
| US-20010011091-A1 | Analgesics | ITO FUMITAKA (JP) | 2001-08-02 | — | — | US | disclosed |
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | ITO FUMITAKA (JP) | 2001-07-26 | — | — | US | disclosed |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | ITO FUMITAKA (JP) | 2001-07-19 | — | — | US | disclosed |
| US-6201007-B1 | OPIOID KAPPA RECEPTOR AGONISTS; ANALGESICS, ANESTHETICS, NEUROPROTECTIVE AND ANTIINFLAMMATORY AGENTS; STROKES, GASTROINTESTINAL DISORDERS | PFIZER INC. | 2001-03-13 | — | — | US | disclosed |
| EP-0934264-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998012177-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (JP) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | OPRL1, OPRD1, OPRK1 | NAMPT 3897/4885HTT 1344/4885POLB 2910/4885 |
| US-20010011091-A1 | Analgesics | OPRL1, OPRK1, OPRD1 | NAMPT 4544/4885HTT 1009/4885POLB 2807/4885 |
| US-20010020024-A1 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists | OPRK1, OPRL1, OPRD1 | NAMPT 4598/4885HTT 1569/4885POLB 1022/4885 |
| US-20010014683-A1 | Analgesics; side effect reduction | OPRL1, OPRK1, OPRD1 | NAMPT 4627/4885HTT 1672/4885POLB 1996/4885 |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | OPRL1, NAP1L1, OPRK1 | NAMPT 4453/4885HTT 103/4885POLB 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.